TELIX PHARMACEUTICALS LIMITED LISTS ON THE AUSTRALIAN SECURITIES EXCHANGE

MELBOURNE, Australia, Nov 15 (Bernama-GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today listed on the Australian Securities Exchange (ASX) after raising $50 million in a fully underwritten Initial Public Offering (IPO).

Telix’s issue price is $65c per share, with a market capitalization of $128 million, placing the IPO as the largest for the Australian ASX biotechnology sector, by capital raised, since 1994. The IPO was fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited.

The IPO has been strongly supported by existing shareholders, which includes both industry partners and domestic institutional investors such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Alium Capital Management and Allan Moss. Fidelity International is a cornerstone investor in the IPO at approximately 10% of the issued capital of the Company.

Telix Co-Founder and CEO Dr. Christian Behrenbruch, “We are delighted with the strong support from our partners, institutional and retail investors to make the IPO success. We believe this is a very exciting opportunity for investors and we look forward to keeping shareholders closely informed of our progress as we develop our oncology product pipeline and engage with commercial partners.”

Proceeds from the IPO will fund the development and completion of clinical trials for Telix’s pipeline in renal (kidney), prostate and brain cancer (glioblastoma), and enable the Company to complete multiple clinical and product development milestones over the next 24 months.

Corporate Contact

Dr Christian Behrenbruch
CEO
Telix Pharmaceuticals Limited
Email: chris@telixpharma.com

Investor and Media Relations

Kyahn Williamson
WE Buchan
Tel: +61 (3) 9866 4722
Email: kwilliamson@buchanwe.com.au

Source : Telix Pharmaceuticals Limited

--BERNAMA